The use of CBD in the treatment of epilepsy is currently generating as much hope as it is questions. For several years, scientific studies and clinical trials have been investigating the potential of phytocannabinoids derived from hemp to reduce seizure frequency, particularly in certain rare and severe forms of epilepsy. Research is progressing rapidly, but all aspects of CBD's efficacy, its potential side effects , and its place in therapeutic protocols for adults and children remain to be clarified. Let's explore the current state of medical knowledge on this sensitive topic.
Understanding epilepsy and its therapeutic challenges
Epilepsy encompasses a range of neurological disorders characterized by recurrent seizures caused by abnormal electrical activity in the brain. While some patients respond well to conventional anti-epileptic drugs, nearly a third have refractory epilepsy, which is resistant to standard treatments.
This reality necessitates a constant search for new solutions to improve the quality of life for those affected. In children with syndromes such as Dravet or Lennox-Gastaut, the complexity of severe forms makes daily management particularly challenging. This context explains why the potential of CBD is attracting so much attention from both the scientific and advocacy communities involved in epilepsy.
How does CBD affect epilepsy?
Cannabidiol (CBD) is a non-psychoactive compound extracted from hemp. Unlike THC, it does not produce a high, but it interacts with various receptors in the endocannabinoid system found in our bodies. Current research suggests that this interaction may help modulate neuronal activity and regulate the hyperexcitability responsible for epileptic seizures.
Advances in the use of CBD for epileptic seizures demonstrate the strong interest in this compound as an alternative therapeutic approach, supported by analyses from various clinical studies. These studies also suggest that CBD influences different neurochemical circuits involved in the transmission of electrical signals. Its exact role remains to be precisely defined, but interest in these mechanisms is growing as the results of clinical trials accumulate, particularly in children with rare forms of epilepsy.
What are the main hypotheses being studied?
The research explores several potential areas of action for cannabidiol :
- Modulation of ion channels involved in neuronal excitability
- Inhibition of pro-convulsant substances in the brain
- Anti-inflammatory effect of CBD on brain tissue
None of these leads have been fully confirmed, but each contributes to a better understanding of the range of possible neuroprotective properties of CBD in the face of epilepsy.
Which phytocannabinoids are being studied in epilepsy?
While CBD is the focus of most research, other molecules present in cannabis and hemp are also being studied. Among them, cannabidivarin (CBDV) seems to show promise, although its efficacy still needs to be confirmed through further clinical trials.
For the moment, only cannabidiol has real scientific validation in the field of epilepsy, while the literature on other phyto-cannabinoids is still emerging.
Results of clinical studies on CBD and epilepsy
The rise of CBD as a complementary treatment for epilepsy is based primarily on randomized clinical trials conducted in pediatric populations with rare syndromes. Results vary depending on the severity and nature of the disorder, as well as the individual profiles of the participants.
A growing body of research highlights the potential benefits of CBD on the frequency and intensity of epileptic seizures, which are of particular interest to families dealing with severe forms of the disease. In Dravet and Lennox-Gastaut syndromes —two emblematic models of severe childhood epilepsy—several studies demonstrate a significant reduction in seizure frequency. Based on this data, cannabidiol is now authorized as an adjunct treatment in certain specific contexts.
What are the observed success rates?
Figures from clinical trials reveal significant variability in response:
| Population | Discount rate ≥50% | Complete cessation of seizures |
|---|---|---|
| Dravet syndrome | 43 to 48% | 5 to 7% |
| Lennox-Gastaut syndrome | 36 to 44% | 3 to 6% |
These figures show that CBD offers significant improvement in some individuals, especially those withepilepsy resistant to multiple drug treatments. However, it's important to remember that a significant proportion of patients do not experience any major changes after starting cannabidiol.
Side effects and tolerance: what does the data say?
Like all epilepsy treatments, CBD is not without side effects. Data from studies point to some commonly reported side effects :
- Drowsiness and decreased alertness
- Decreased appetite
- Diarrhea, mild nausea
- Transient elevation of liver enzymes
The vast majority of observed events remain mild and reversible. However, specialized medical monitoring is necessary, particularly when combined with other anticonvulsants. Overall, CBD is considered to be well tolerated in the medium term, making its use a viable option for certain categories of patients under strict supervision.
Children, adults and forms of epilepsy concerned
In practice, the documented benefits of CBD primarily concern children with rare and severe epilepsy , including Dravet and Lennox-Gastaut syndromes . For other types of epilepsy, the documentation remains limited and often restricted to preliminary or observational studies .
In adults, few controlled studies formally validate the efficacy of CBD in treating epilepsy. Access to cannabidiol outside of the specific indications approved by health authorities must therefore remain exceptional and regulated.
Can CBD be considered a universal solution against epilepsy?
Currently, CBD appears more as a promising and complementary approach than a general solution applicable to all epileptic patients. This observation is shared by the majority of experts, prompting further clinical trials to broaden or refine the product's indications.
The positive impact observed inrefractory epilepsy should not overshadow the need for caution regarding more common forms, which still require significant scientific work before recommending CBD in all clinical situations.
Legislation, issuance and medical support
The prescription of cannabidiol for medical use remains strictly regulated. In many European countries, only patients suffering from severe and debilitating forms of the disease receive official authorization, through standardized products. There is therefore a major difference between the regulated use of pharmaceutical CBD and freely marketed wellness products.
Any trial of CBD in the treatment of epilepsy must be coordinated by an experienced medical team. This allows for monitoring of side effects, drug interactions, and fine-tuning of the protocol.
Frequently asked questions about CBD and epilepsy
Can CBD replace traditional medications for treating epilepsy?
CBD is not generally used as a complete substitute for traditional epilepsy medications. Rather, it is used as a complementary treatment for individuals with severe or refractory forms of epilepsy. Stopping or modifying conventional treatment should always be done in consultation with a specialist neurologist.
- Dose adjustment
- Monitoring interactions
- Additional role only validated in certain syndromes
What are the risks associated with the side effects of CBD in children?
The main side effects include drowsiness, fatigue, and even digestive problems. Regular liver monitoring is sometimes necessary, as elevated liver enzymes have been observed in some children. These effects necessitate close monitoring when initiating CBD treatment for pediatric epilepsy.
- Increased fatigue, especially at the start of treatment
- Decreased appetite
- Possible interference with other therapies
| Side effect | Frequency (%) |
|---|---|
| Drowsiness | 20-30 |
| Decreased appetite | 15-25 |
Are there differences in effectiveness between adults and children?
Most of the evidence of efficacy concerns children with severe or rare epilepsy. In adults, studies remain quite limited and the results less consistent. The lack of long-term data on its use necessitates considerable caution in this age group.
- Robust evidence for Dravet and Lennox-Gastaut syndrome in children
- Insufficient data regarding adult epilepsy
Are all CBD products suitable for treating epilepsy?
No, only products extracted using controlled methods and tested in clinical trials are suitable for the medical treatment of epilepsy. Oils or supplements sold over the counter do not guarantee the expected safety or efficacy, and their quality varies considerably. It is recommended to follow only a protocol validated by a healthcare professional.
- Secure prescription
- Product titrated and analyzed
- Constant medical monitoring
Editor-in-Chief specializing in CBD
Julien, born on July 17, 1978, in the Paris region, is a prominent writer and expert in the field of CBD products. Following his studies, Julien developed a passion for natural remedies, including CBD. In 2022, he joined the CBD.fr team as an expert and regular contributor. Thanks to his scientific expertise and clear writing style, Julien helps demystify the complexities of CBD, while highlighting its benefits and potential applications through his articles and conference presentations.
